Core Viewpoint - The stock performance of Qiming Medical-B (02500.HK) has been weak, with a recent price of HKD 2.81, down 2.43% from the previous day, and a cumulative decline of 6.02% over five days, indicating a price below the 20-day moving average [1] Group 1: Company Performance - As of February 13, Qiming Medical-B's stock price is HKD 2.81, reflecting a decline of 2.43% from the previous day and a total drop of 6.02% over the past five days [1] - The stock is currently trading below the 20-day moving average, indicating a bearish trend [1] Group 2: Industry Insights - The ADC (Antibody-Drug Conjugate) commercialization process is accelerating, with expectations of rapid growth in the next 3-5 years, highlighting potential investment opportunities in innovative pharmaceutical companies and CXO firms [2] - The overall activity in the medical device sector remains robust, suggesting a favorable environment for companies in this space [2] Group 3: Recent Events - Recent developments in the pharmaceutical and biotechnology industry, particularly in the ADC drug sector, include the acceptance of the dual-antibody ADC listing application by Bai Li Tian Heng and updates to the Drug Administration Law that support segmented contract manufacturing, providing policy support for industry collaboration [3] - These dynamics may indirectly influence the long-term development environment for medical device companies [3]

Group 1 - The core viewpoint of the news highlights significant advancements in the biotech sector, particularly in the collaboration between Innovent Biologics and Eli Lilly, which focuses on new drug development in oncology and immunology, with a deal size exceeding expectations [1] - The collaboration employs a "China PoC + global development" model, leveraging Innovent's efficient clinical validation capabilities in China while utilizing Eli Lilly's global commercialization network to mitigate risks, marking a key step in the globalization of Chinese innovative pharmaceutical companies [1] - The assets involved in the collaboration, such as IBI363 and IBI343, have entered global multi-center Phase III clinical trials, with a combined potential market space of $60 billion [1] Group 2 - The ADC commercialization process is accelerating, with 20 ADC drugs approved globally, six of which have consistently been in the "billion-dollar club" for two years; approximately 60 are in Phase III clinical trials or awaiting market approval [2] - Local companies are increasingly gaining advantages due to their self-commercialization capabilities, as seen with Rongchang Biologics transitioning from outsourcing to in-house production, and Keren Biotechnology and Baillie Tianheng accelerating the establishment of their own production bases [2] - The Hong Kong Innovation Drug ETF has seen a strong performance, with a 3.10% increase as of February 10, 2026, and a total scale of 25.98 billion yuan, indicating a positive trend in investment within the sector [2]